LivaNova PLC announced that the U.S. Food and Drug Administration granted pre‑market approval for its aura6000™ System on March 19 2026. The device is a proximal hypoglossal nerve‑stimulation system designed to treat adult patients with moderate to severe obstructive sleep apnea (OSA).
The approval is notable because the aura6000™ System is the first hypoglossal nerve‑stimulation therapy cleared without a complete concentric collapse contraindication, giving LivaNova a broader treatment envelope than competitors. The system’s MRI‑compatibility and six‑electrode design are additional differentiators that may improve patient outcomes and expand market reach.
With FDA clearance, LivaNova can begin commercial sales of the aura6000™ System in the United States, creating a new high‑margin revenue stream that complements its existing epilepsy and cardiopulmonary businesses. The company’s neuromodulation segment grew 7 % on a reported basis in 2025, and the new OSA product line is expected to accelerate that growth trajectory.
The OSA device market was valued at $9.7 billion in 2024 and is projected to reach $18.3 billion by 2032. LivaNova’s Investor Day presentation in November 2025 projected OSA revenue of $200 million to $400 million by 2030, underscoring the significant upside of the new product. The lack of a complete concentric collapse contraindication positions the aura6000™ System to capture a larger share of this expanding market.
Financially, LivaNova reported Q4 2025 revenue of $360.9 million and full‑year 2025 revenue of $1.39 billion, up 10.7 % on a reported basis from the prior year. Adjusted diluted earnings per share rose to $3.90 from $3.38 in 2024. The company’s 2026 guidance calls for revenue growth of 6.0 % to 7.0 % and adjusted diluted EPS of $4.15 to $4.25, reflecting confidence in the neuromodulation pipeline and the new OSA product.
The aura6000™ System’s clinical validation comes from the OSPREY randomized controlled trial, which demonstrated a 65 % responder rate at 12 months. This robust efficacy data underpins the FDA’s approval and supports the company’s claim of a differentiated technology capable of treating a broader range of challenging patients.
In a statement released with the approval, CEO Vladimir Makatsaria highlighted the company’s progress: “In 2025, LivaNova delivered double‑digit revenue growth, meaningful operating margin expansion, and robust cash generation, reflecting strong execution in both our Cardiopulmonary and Epilepsy businesses.” He added that the OSA launch “is the first stage of a new chapter where we have a clear right to win based on rigorous clinical evidence and a differentiated technology.” Chief Innovation Officer Ahmet Tezel noted that the approval “marks a transformative moment for LivaNova and represents a major step forward for patients struggling with inadequately treated OSA.”
LivaNova is preparing a next‑generation version of the aura6000™ System for FDA supplement review, with MRI compatibility and enhanced battery technology. The company expects to launch this next‑generation system in the first half of 2027, further strengthening its neuromodulation portfolio.
The market reacted positively to the approval, with analysts revising earnings estimates upward to reflect the new revenue potential and the company’s optimistic guidance. The approval is expected to reinforce LivaNova’s strategic focus on neuromodulation and to broaden its product offering in a high‑growth OSA market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.